CGEM Stock Analysis: Cullinan Oncology | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.131m USD | 12M Return: 125.7% | Charts, Fundamentals & Technical Analysis

Bispecific Antibodies, Autoimmune Therapies, Cancer Therapies, Small Molecules
Total Rating 48
Safety 66
Buy Signal 0.11
Biotechnology
Industry Rotation: +16.7
Market Cap: 1.13B
Avg Turnover: 20.5M
Risk 3d forecast
Volatility70.8%
VaR 5th Pctl11.3%
VaR vs Median-3.39%
Reward TTM
Sharpe Ratio1.35
Rel. Str. IBD95.6
Rel. Str. Peer Group76.8
Character TTM
Beta1.226
Beta Downside1.280
Hurst Exponent0.487
Drawdowns 3y
Max DD80.41%
CAGR/Max DD0.25
CAGR/Mean DD0.44
EPS (Earnings per Share) EPS (Earnings per Share) of CGEM over the last years for every Quarter: "2021-06": -0.36, "2021-09": -0.4, "2021-12": -0.74, "2022-03": -0.27, "2022-06": 3.77, "2022-09": -0.54, "2022-12": -0.59, "2023-03": -1.42, "2023-06": -0.82, "2023-09": -0.91, "2023-12": -0.54, "2024-03": -0.86, "2024-06": -0.75, "2024-09": -0.69, "2024-12": -0.73, "2025-03": -0.74, "2025-06": -1.07, "2025-09": -0.77, "2025-12": -0.77, "2026-03": -0.75,
Last SUE: 0.62
Qual. Beats: 0
Revenue Revenue of CGEM over the last years for every Quarter: 2021-06: 0, 2021-09: 0, 2021-12: -37.848114, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: 0,
Last SUE: 0.00
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Rs Leader
Confidence

Seasonality 5.5 years of data

Jan +9.1% 0
Feb +20.6% 0
Mar -8.4% 34
Apr +6.2% 0
May +16.2% 33
Jun +4.4% 0
Jul +10.1% 49
Aug +2.1% 15
Sep -11.3% 46
Oct +5.5% 16
Nov -6.4% 17
Dec -2.7% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CGEM Cullinan Oncology

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing therapies for autoimmune diseases and cancer. Its pipeline includes CLN-978 (CD19xCD3 bispecific T cell engager) and velinotamig (BCMAxCD3 bispecific), both in Phase 1 trials for autoimmune diseases, as well as CLN-049 (FLT3xCD3 bispecific) in Phase 1 trials for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also advancing zipalertinib, an oral irreversible EGFR inhibitor, in the Phase 2b REZILIENT1 trial for EGFR ex20ins non-small cell lung cancer.

Cullinan has structured its development strategy around licensing and co-development partnerships, including agreements with Chongqing Genrix Biopharmaceutical (for velinotamig), Taiho Pharmaceutical (for zipalertinib), and Adimab (for antibody discovery and optimization). The company was incorporated in 2016, IPOd in January 2021, and rebranded from Cullinan Oncology to Cullinan Therapeutics in April 2024.

As a clinical-stage biotech, Cullinan does not yet have approved commercial products and relies on pipeline progression, partnership payments, and capital markets to fund its R&D operations. Bispecific T cell engagers, which anchor several of its programs, are an emerging class of immunotherapy designed to bind both a tumor or immune cell target and T cells to drive targeted immune activity.

Headlines to Watch Out For
  • Phase 1 data readouts for CLN-978 and velinotamig
  • Zipalertinib REZILIENT1 EGFR lung cancer trial advances
  • Cash burn raises dilution risk amid R&D spending
Piotroski VR-10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.44 > 0.02 and ΔFCF/TA -18.43 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.44 > 3% & CFO -178.6m > Net Income -221.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.28 > 1.5 & < 3
Outstanding Shares: last quarter (59.2m) vs 12m ago 0.50% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 7.57
A: 0.81 (Total Current Assets 361.4m - Total Current Liabilities 35.2m) / Total Assets 403.0m
B: -1.58 (Retained Earnings -637.8m / Total Assets 403.0m)
C: -0.45 (EBIT TTM -221.0m / Avg Total Assets 491.3m)
D: 9.95 (Book Value of Equity 366.2m / Total Liabilities 36.8m)
Altman-Z'' = 7.57 = AAA
What is the price of CGEM shares?

As of July 05, 2026, the stock is trading at USD 17.63 with a total of 1,074,800 shares traded. Over the past week, the price has changed by -4.60%, over one month by +15.91%, over three months by +18.16% and over the past year by +125.74%.

Current recommended Stop Loss: 15.20 (which is 13.8% or 2 ATR below the current price).

Is CGEM a buy, sell or hold?

Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.

  • StrongBuy: 8
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CGEM price?
Analysts Target Price 31.6 79%
Cullinan Oncology (CGEM) - Fundamental Data Overview as of 29 June 2026
Market Cap USD = 1.13b (1.13b USD * 1.0 USD.USD)
P/E Forward = 6.7385
P/S = 25.8559
P/B = 3.0748
Revenue TTM = 0.0 USD
EBIT TTM = -221.0m USD
EBITDA TTM = -220.7m USD
Long Term Debt = 1.66m USD (estimated: total debt 2.38m - short term 725k)
Short Term Debt = 725k USD (from shortTermDebt, last quarter)
Debt = 2.38m USD (from shortLongTermDebtTotal, last quarter) (leases 2.38m already included)
Net Debt = -349.5m USD (calculated: Debt 2.38m - CCE 351.9m)
Enterprise Value = 781.3m USD (1.13b + Debt 2.38m - CCE 351.9m)
 Interest Coverage Ratio = unknown (Ebit TTM -221.0m / Interest Expense TTM 0.0)
 EV/FCF = -4.37x (Enterprise Value 781.3m / FCF TTM -178.7m)
FCF Yield = -22.87% (FCF TTM -178.7m / Enterprise Value 781.3m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 311k) / Revenue TTM)
 Tobins Q-Ratio = 1.94 (Enterprise Value 781.3m / Total Assets 403.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.38m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -174.6m (EBIT -221.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.28 (Total Current Assets 361.4m / Total Current Liabilities 35.2m)
Debt / Equity = 0.01 (Debt 2.38m / totalStockholderEquity, last quarter 366.2m)
 Debt / EBITDA = 1.58 (negative EBITDA) (Net Debt -349.5m / EBITDA -220.7m)
 Debt / FCF = 1.96 (negative FCF - burning cash) (Net Debt -349.5m / FCF TTM -178.7m)
 Total Stockholder Equity = 429.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.99% (Net Income -221.0m / Total Assets 403.0m)
RoE = -51.45% (Net Income TTM -221.0m / Total Stockholder Equity 429.6m)
RoCE = -51.25% (EBIT -221.0m / Capital Employed (Equity 429.6m + L.T.Debt 1.66m))
 RoIC = -47.38% (negative operating profit) (NOPAT -174.6m / Invested Capital 368.6m)
 WACC = 10.27% (E(1.13b)/V(1.13b) * Re(10.29%) + D(2.38m)/V(1.13b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 15.52%
 [DCF] Fair Price = unknown (Cash Flow -178.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.62 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.85 | Chg30d=+0.86% | Revisions=+57% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.86 | Chg30d=+0.71% | Revisions=+38% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.00 | Chg30d=+6.60% | Revisions=+50% | GrowthEPS=+10.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.53 | Chg30d=-1.57% | Revisions=+44% | GrowthEPS=+15.7% | GrowthRev=+126.3%
[Analyst] Revisions Ratio: +64% (up=19, down=3)